AIM: This study aims to investigate the mode of action of a novel sirtuin 
inhibitor (BZD9L1) and its associated molecular pathways in colorectal cancer 
(CRC) cells.
MATERIALS & METHODS: BZD9L1 was tested against metastatic CRC cell lines to 
evaluate cytotoxicity, cell cycle and apoptosis, senescence, apoptosis related 
genes and protein expressions, as well as effect against major cancer signaling 
pathways.
RESULTS & CONCLUSION: BZD9L1 reduced the viability, cell migration and colony 
forming ability of both HCT 116 and HT-29 metastatic CRC cell lines through 
apoptosis. BZD9L1 regulated major cancer pathways differently in CRC with 
different mutation profiles. BZD9L1 exhibited anticancer activities as a 
cytotoxic drug in CRC and as a promising therapeutic strategy in CRC treatment.